DEVELOPMENT AND STABILITY EVALUATION OF ATORVASTATIN EXTEMPORANEOUS ORAL SUSPENSION FOR ELDERLY PATIENTS
DOI:
https://doi.org/10.22159/ijap.2025v17i1.52519Keywords:
Atorvastatin, Extemporaneous, Formulation, Suspension, StabilityAbstract
Objective: This study aims to develop an extemporaneous oral suspension formulation of atorvastatin (ATV) and evaluate its stability.
Methods: ATV extemporaneous oral suspension was developed by preparation using different suspension vehicles. The developed formulation was stored at ambient temperature (30±2 °C) and refrigerated temperature (4±2 °C) to evaluate its physical and chemical stability. The formulation was also exposed to 3% hydrogen peroxide (H2O2), 1 M hydrochloric acid (HCl), and 1 M sodium hydroxide (NaOH) to evaluate its stability under stress conditions. ATV was analyzed using High-Performance Liquid Chromatography (HPLC), which was validated prior to use.
Results: A vehicle containing 0.6% sodium carboxymethyl cellulose (SCMC) was suitable for the preparation of ATV extemporaneous oral suspension. The HPLC method was found to have linearity covering the range of 10–100 mg/ml with a correlation coefficient (r) greater than 0.99. Accuracy and precision were in the range of 99–110% and below 11 %RSD, respectively. The pH and viscosity of the developed formulation stored under ambient and refrigerated temperatures did not differ over 7 d, while the re-dispersibility time of the formulation stored in refrigerator shifted to higher more slowly than the formulation stored at ambient temperature. The % ATV remaining over 7 d was 92.02–106.67% at 30±2 °C and 99.64–107.58% at 4±2 °C. After being subjected to stress conditions, ATV remained stable under oxidation and alkaline conditions, while it significantly degraded under acidic conditions, remaining 24.27%.
Conclusion: The developed ATV extemporaneous oral suspension using a suspension vehicle containing 0.6% SCMC was chemically stable for at least 7 d at 30±2 °C and 4±2 °C. However, this formulation should be preferably stored at refrigerator temperature for use within 7 d to maintain both chemical and physical stability. The formulation was not stable under acid-stress conditions.
Downloads
References
Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin. 2003;19(6):540-56. doi: 10.1185/030079903125002225, PMID 14594527.
Markowska A, Antoszczak M, Markowska J, Huczynski A. Statins: HMG-CoA reductase inhibitors as potential anticancer agents against malignant neoplasms in women. Pharmaceuticals (Basel). 2020 Nov 25;13(12):422. doi: 10.3390/ph13120422, PMID 33255609.
Zaid AN, Assali M, Zalmout S, Basheer A. Compounding and stability evaluation of atorvastatin extemporaneous oral suspension using tablets or pure powder. Eur J Hosp Pharm. 2017;24(3):157-61. doi: 10.1136/ejhpharm-2016-000913, PMID 31156928.
Horodinschi RN, Stanescu AM, Bratu OG, Pantea Stoian A, Radavoi DG, Diaconu CC. Treatment with statins in elderly patients. Medicina (Kaunas). 2019;55(11):721. doi: 10.3390/medicina55110721, PMID 31671689.
Komesmuneeborirak P, Werawatganone P, Muangsiri W. Amphotericin B topical extemporaneous preparations for the treatment of non-dermatophytic onychomycosis. Asian J Pharm Clin Res. 2020;13:135-9.
Ali H, Saad R, Ahmed A, El-Haj B. Extemporaneous furosemide suspensions for pediatrics use prepared from commercially available tablets. Int J Curr Pharm Rev Res. 2016;5:116-38.
Atipairin A, Woradechakul C, Chee KS, Sawatdee S, Yoon AS. Method validation for determination of sildenafil citrate in extemporaneous oral suspension. Int J Pharm Pharm Sci. 2014;6:131-6.
Popy FA, Dewan I, Parvin MN, Islam SM. Evaluation of in vitro equivalence for tablets containing the poorly water-soluble compound atorvastatin. Dissolution Technol. 2012;19(4):30-3. doi: 10.14227/DT190412P30.
Yagnesh TN, Rada S. Pharmaceutical suspensions: patient compliance oral dosage forms. World J Pharm Pharm Sci. 2016 Jan:5(12)1471-537. doi: 10.20959/wjpps201612-8159.
Falconer JR, Steadman KJ. Extemporaneously compounded medicines. Aust Prescr. 2017;40(1):5-8. doi: 10.18773/austprescr.2017.001, PMID 28246428.
Dysars LP, Dysars LP, Ricci Junior EP, Ricci Junior E. Preparation of extemporaneous oral liquid in the hospital pharmacy. Braz J Pharm Sci. 2020;56. doi: 10.1590/s2175-97902019000418358.
Winiarski AP, Infeld MH, Tscherne R, Bachynsky M, Rucki R, Nagano Mate K. Preparation and stability of extemporaneous oral liquid formulations of oseltamivir using commercially available capsules. J Am Pharm Assoc (2003). 2007;47(6):747-55. doi: 10.1331/JAPhA.2007.06125, PMID 18032138.
Mohiuddin A. Extemporaneous compounding: cautions controversies and convenience. IJMHS. 2019;9(1):252-64. doi: 10.15520/ijmhs.v9i1.2420.
ICH. Validation of analytical procedures: text and Methodology; 2005. p. Q2 (R1).
United States Pharmacopeia. 42-national formulary. General Chapter, 795, pharmaceutical compounding nonsterile preparations. Rockville MD: US Pharmacopeial Convention; 2018. p. 37.
United States Pharmacopeia. 42-national formulary. General chapter, 659, packaging and storage requirements. Rockville, MD: US Pharmacopeial Convention; 2018. p. 37.
25th Asean Consultative Committee for Standards and Quality (ACCSQ) Pharmaceutical Product Working Group (PPWG). ASEAN guideline on stability study of drug product; 2018. p. 1-42.
United States Pharmacopeia. USP monographs. Atorvastatin calcium tablets. USP-NF. Rockville MD: United States Pharmacopeia; 2024.
Food Drug Administration. Reviewer guidance: validation of chromatographic methods. Center for Drug Evaluation and Research; Nov 1994.
Deicke A, Suverkrup R. Dose uniformity and redispersibility of pharmaceutical suspensions. I: quantification and mechanical modelling of human shaking behaviour. Eur J Pharm Biopharm. 1999;48(3):225-32. doi: 10.1016/S0939-6411(99)00045-4, PMID 10612033.
Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs a review. J Pharm Anal. 2014;4(3):159-65. doi: 10.1016/j.jpha.2013.09.003, PMID 29403878.
Kadsomboon O. Compounding of pediatric extemporaneous favipiravir oral suspensions in community hospital. J Public Hlth Dev. 2022;2(1):62-77.
Waterman KC, Adami RC. Accelerated aging: prediction of chemical stability of pharmaceuticals. Int J Pharm. 2005;293(1-2):101-25. doi: 10.1016/j.ijpharm.2004.12.013, PMID 15778049.
Jadhav PS, Jamkar PM, Avachat AM. Stability indicating method development and validation for simultaneous estimation of atorvastatin calcium and celecoxib in bulk and niosomal formulation by RP-HPLC. Braz J Pharm Sci. 2015;51(3):653-61. doi: 10.1590/S1984-82502015000300017.
Manallack DT, Prankerd RJ, Yuriev E, Oprea TI, Chalmers DK. The significance of acid/base properties in drug discovery. Chem Soc Rev. 2013;42(2):485-96. doi: 10.1039/c2cs35348b, PMID 23099561.
Manousi N, Wojnowski W, Plotka Wasylka J, Samanidou V. Blue applicability grade index (BAGI) and software: a new tool for the evaluation of method practicality. Green Chem. 2023;25(19):7598-604. doi: 10.1039/D3GC02347H.
Pena Pereira F, Wojnowski W, Tobiszewski M. Agree analytical greenness metric approach and software. Anal Chem. 2020;92(14):10076-82. doi: 10.1021/acs.analchem.0c01887, PMID 32538619.
Plotka Wasylka J, Wojnowski W. Complementary green analytical procedure index (ComplexGAPI) and software. Green Chem. 2021;23(21):8657-65. doi: 10.1039/D1GC02318G.
Published
How to Cite
Issue
Section
Copyright (c) 2025 SIRIKANYA KAEWPRADIT, YUWAKORN SIRIPITHAYA, CHUTIMA JANTARAT
This work is licensed under a Creative Commons Attribution 4.0 International License.
